Probable levetiracetam-related serum alkaline phosphatase elevation

BMC Neurology

Volumn 12, Issue , 2012, Pages

  Xiong, Nian ^a   Hou, Lingling ^a,b   Lu, Na ^a   Mohamed, Asrah A ^a   Wang, Tao ^a   Huang, Yaling ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN IRON AND STEEL GROUP CORPORATION   (China)

Author keywords

Antiepileptic drugs; Epilepsy; Hepatotoxicity; Levetiracetam; Serum alkaline phosphatase

Indexed keywords

ALKALINE PHOSPHATASE; CREATINE KINASE; CREATINE KINASE MB; ETIRACETAM; LACTATE DEHYDROGENASE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANTICONVULSANT THERAPY; ARTICLE; BENIGN CHILDHOOD EPILEPSY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CREATINE KINASE BLOOD LEVEL; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; INFANT; LACTATE DEHYDROGENASE BLOOD LEVEL; MONOTHERAPY; SIDE EFFECT;

ALKALINE PHOSPHATASE; ANTICONVULSANTS; BIOLOGICAL MARKERS; CHILD; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; PIRACETAM; TREATMENT OUTCOME;

EID: 84866493408     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-12-97     Document Type: Article

References (12)

1. Leppik IE. Issues in the treatment of epilepsy. Epilepsia 2001, 42(Suppl 4):1-6.
2. Wheless JW. Levetiracetam in the treatment of childhood epilepsy. Neuropsychiatr Dis Treat 2007, 3(4):409-421. 2655081, 19300570.
3. Krief P, Li K, Maytal J. Efficacy of levetiracetam in children with epilepsy younger than 2 years of age. J Child Neurol 2008, 23(5):582-584. 10.1177/0883073807309781, 18448575.
4. Li S, Cao J, Xiao N, Cai F. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. J Child Neurol 2010, 25(5):609-613. 10.1177/0883073809342489, 19779208.
5. Perucca E. Designing clinical trials to assess antiepileptic drugs as monotherapy: difficulties and solutions. CNS Drugs 2008, 22(11):917-938. 10.2165/00023210-200822110-00003, 18840033.
6. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004, 101(26):9861-9866. 10.1073/pnas.0308208101, 470764, 15210974.
7. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006, 69(3):273-294. 10.1016/j.eplepsyres.2006.02.004, 1562526, 16621450.
8. Briggs DE, French JA. Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Saf 2004, 3(5):415-424. 10.1517/14740338.3.5.415, 15335297.
9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30(2):239-245. 10.1038/clpt.1981.154, 7249508.
10. Narayanan S. Serum alkaline phosphatase isoenzymes as markers of liver disease. Ann Clin Lab Sci 1991, 21(1):12-18.
11. Dahlin MG, Wide K, Ohman I. Age and comedications influence levetiracetam pharmacokinetics in children. Pediatr Neurol 2010, 43(4):231-235. 10.1016/j.pediatrneurol.2010.05.008, 20837299.
12. Borusiak P, Langer T, Heruth M, Karenfort M, Bettendorf U, Jenke AC. Antiepileptic Drugs and Bone Metabolism in Children: Data from 128 Patients. J Child Neurol 2012,